The Division of Molecular Medicine and Gene Therapy is located at the Biomedical Center (BMC), Lund University, Sweden. Established as a joint venture between the Medical Faculty at Lund University and the Hematology Clinic at Lund University Hospital, our mission is to translate basic science to clinical applications.
Our research focuses on hematopoiesis, the continuous and dynamic process of blood cell formation. The laboratory consists of eight closely collaborating research groups that all share a common interest in investigating the properties of blood stem cells to eventually understand and treat hematological disorders.
Five of our researchers belong to the Hemato-Linné Excellence Linnaeus Research Environment funded by The Swedish Research Council and Lund University. Several of the groups are engaged in StemTherapy, a Strategic Research Area for Stem Cells and Regenerative Medicine that is also supported by The Swedish Research Council.
The Division of Molecular Medicine and Gene Therapy looks back at a successful and inspiring ISEH meeting in San Diego.
Congratulations to Sofie Singbrant Söderberg on her success in being selected to chair the ISEH New Investigator Committee during the time period 2016 – 2018. The New Investigator Committee provides opportunities for junior scientists to grow in their careers, such as the organization of educational sessions and networking events with established ISEH scientists.
- I feel truly honored to be selected chair for a committee that consists of such talented, creative and driven new investigators from all over the world. I’m excited to develop and improve opportunities for young researchers to learn from established faculty in our field, both through sessions at the annual meetings and the educational webinars and articles, as well as social media updates and online journal clubs that we provide throughout the year, says Sofie Singbrant Söderberg, Assistant Professor at the Division of Molecular Medicine and Gene Therapy.
In addition, Sandra Capellera Garcia, PhD student in the Flygare group, received the T. Ray Bradley Award during the New Investigator Award session in recognition for her outstanding work on defining the minimal factors required for erythropoiesis.
Congratulations to both of you!
Congratulations to Johan Richter on his success in being selected to give a plenary presentation during the Presidential Symposium at the EHA Annual Congress in Copenhagen, June 9-12, 2016. An attentive audience of more than 4,000 followed his talk about results of the EURO-SKI study, a multicenter open label trial estimating the persistence of molecular remission in Chronic Myeloid Leukemia (CML) patients after stopping Tyrosine Kinase Inhibitors (TKI).
- We hope that the results from this study can form the basis for new treatment guidelines and help move the concept of stopping TKI-therapy in CML patients with a deep molecular response into standard clinical practice, says Johan Richter, Professor at the Division of Molecular Medicine and Gene Therapy and Senior Consultant in Hematology at Skåne University Hospital.
Congratulations to Sandra Capellera-Garcia et al. whose paper "Defining the Minimal Factors Required for Erythropoiesis through Direct Lineage Conversion" was published today in Cell Reports. In this study, Sandra and her colleagues identified the transcription factors Gata1, Tal1, Lmo2, and c-Myc as the minimal set of factors required for direct conversion of mouse and human fibroblasts into erythroid progenitors. These findings increase our understanding of erythroid lineage development and move researchers one step closer to establishing protocols for red blood cell production in vitro.
Professor Gerald de Haan from the University Medical Center Groningen, The Netherlands, will be visiting Lund on June 3 in connection with Matilda Billing's thesis defence.
He will give a lecture entitled "Aging of hematopoietic stem cells" on Friday June 3 at 11 am in the Segerfalk Lecture Hall, BMC A10.
Host: Stefan Karlsson